Re: Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
The cardiovascular endpoint is very encouraging but was the rate of UTIs, recurrent, complicated or just simple UTI measured please ? With antimicrobial stewardship being such a hot topic, presumably the infection rate needs to be known before widespread roll-out of gliflozin prescribing. UTIs are stated to be a common side-effect for all gliflozins. Reduced cardiovacsular harm but at what cost ?
Janet Thomas (Mrs)
Patient Safety Pharmacist
Wrexham Maelor Hospital
Competing interests: No competing interests